AI Article Synopsis
- Pyrimidine 5'nucleotidase I and II enzyme activities were studied in peripheral mononuclear cells from patients with acute leukaemias to assess their role in diagnosis and monitoring therapy.
- Blood samples were collected from 40 untreated leukaemia patients and 40 healthy controls, and enzyme levels were measured using High-Performance Liquid Chromatography (HPLC) for statistical analysis.
- The results showed significantly elevated levels of both enzymes in leukaemia patients compared to controls, indicating their potential as diagnostic markers, but they did not predict therapeutic outcomes or survival.
Article Abstract
Background And Objective: Pyrimidine 5'nucleotidase I and II activities of peripheral mononuclear cells were studied to evaluate their role in diagnosis, assessment of therapy and follow up of remission in acute leukaemias.
Design And Methods: Blood samples were obtained from 40 untreated patients with acute lymphoblastic and myeloid leukaemia and 40 healthy controls, before the therapy and after remission. The correlation between the activity of the enzymes and the efficacy of therapy were established. The enzyme activities were measured by High-Performance Liquid Chromatography (HPLC), using the method described by Amici. For statistical analysis, Mann-Whitney U, Kruskal-Wallis and Wilcoxon methods were used.
Results: Before the therapy, Pyrimidine 5'nucleotidase I levels in the leukaemic group were found to be significantly elevated when compared to the control group (p<0.001). Also Pyrimidine 5'nucleotidase II levels were significantly elevated before the therapy and during remission (p<0.02 and p<0.001 respectively). The isoenzyme activities were compared in patients who were in remission, who did not respond to therapy and in patients who died during the therapy, but no significant difference was found.
Interpretation And Conclusions: We concluded that, Pyrimidine 5'nucleotidase I and II activities can be used as markers for diagnosis and follow up of remission in patients with acute leukaemia. But, they can not have predictive value for prognosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer.
Oncologist
December 2024
HonorHealth Research Institute, Scottsdale, AZ, United States.
Background: Chemotherapy-induced peripheral neuropathy (CIPN), a common problem, can impair function and quality of life in patients, potentially limiting chemotherapy and adversely affecting outcomes.
Methods: This trial compared investigational hand therapy intervention (Investigational) compared with a traditional occupational therapy approach (Traditional) to prevent CIPN in patients with pancreatic cancer receiving gemcitabine and albumin-bound paclitaxel containing regimens.
Results: forty-nine patients were enrolled with 40 evaluable for statistical analysis (21 Investigational/19 Traditional).
Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1,3)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase.
J Med Chem
October 2024
Center of Drug Discovery, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China.
Ecto-5-nucleotidase (CD73) is overexpressed in a variety of cancers and associated with the immunosuppressive tumor microenvironment, making it an attractive target for cancer immunotherapy. Herein, we designed and synthesized a series of novel (pyridazine-3-yl)pyrimidine-2,4(1,3)-dione derivatives as CD73 inhibitors. These compounds exhibited remarkable inhibitory activity against CD73 in both enzymatic biochemical and cellular assays.
View Article and Find Full Text PDFThe potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer.
Front Immunol
October 2024
Escola de Medicina, Programa de Pós-Graduação em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Article Synopsis
- Purines and pyrimidines are key signaling molecules in tumors that influence the immune response against cancer, with purinergic signaling pathways significantly impacting cancer development and progression.
- CD39 and CD73, enzymes that convert ATP and ADP into adenosine, contribute to immunosuppression in various cancers, making them potential targets for immunotherapy.
- This review focuses on the critical role of the adenosine/CD73 pathway in prostate cancer treatment, advocating for anti-CD73 as a promising pharmacological strategy to improve patient outcomes.
[Metabolic engineering of for thymidine production].
Sheng Wu Gong Cheng Xue Bao
August 2024
School of Biological Engineering, Tianjin University of Science and Technology, Tianjin 300457, China.
Thymidine, as a crucial precursor of anti-AIDS drugs (e.g., zidovudine and stavudine), has wide application potential in the pharmaceutical industry.
View Article and Find Full Text PDFExpression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
Neoplasia
July 2024
Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Centre Goettingen, Robert-Koch-Straße 40, 37075 Goettingen, Germany; Clinical Research Unit KFO5002, University Medical Center Goettingen, Goettingen, Germany. Electronic address:
Background: Pancreatic ductal adenocarcinoma (PDAC) poorly responds to antineoplastic agents. Discrepancies between preclinical success and clinical failure of compounds has been a continuous challenge and major obstacle in PDAC research.
Aim: To investigate the association of the tumor microenvironment (TME) composition and gemcitabine metabolizing enzyme (GME) expression in vitro and several in vivo models.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!